A Commentary on the Safety of Probiotics

Gastroenterology Clinics of North America

Volumn 41, Issue 4, 2012, Pages 869-876

  Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bifidobacterium; Commensals; Lactobacillus; Microbiota

Indexed keywords

INFLAMMASOME; KERATINOCYTE GROWTH FACTOR; PLACEBO; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA;

ACUTE PANCREATITIS; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BIFIDOBACTERIUM; COMMENSAL; DRUG LABELING; DRUG SAFETY; ENTERITIS; GENETIC ENGINEERING; HELICOBACTER PYLORI; HOST SUSCEPTIBILITY; HUMAN; INTESTINE ISCHEMIA; LACTOBACILLUS; MICROBIAL CONTAMINATION; NONHUMAN; OBESITY; QUALITY CONTROL; REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT;

DRUG RESISTANCE, BACTERIAL; GASTROINTESTINAL TRACT; HUMANS; OBESITY; PANCREATITIS; PROBIOTICS;

EID: 84867944463     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.08.006     Document Type: Review

References (49)

1. Chantler C. The role and education of doctors in the delivery of health care. Lancet 1999, 353:1178-1181.
2. FAO/WHO Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. Available at: Accessed June 4, 2012. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
3. Shanahan F., Stanton C., Ross P., et al. Pharmabiotics: bioactives from mining host-microbe-dietary interactions. Functional Food Reviews 2009, 1:20-25.
4. Lebeer S., Vanderleyden J., De Keersmaecker S.C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 2010, 8:171-184.
5. Round J.L., Lee S.M., Li J., et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011, 332:974-977.
6. Elinav E., Strowig T., Kau A.L., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:1-13.
7. Franchi L., Kamada N., Namamura Y., et al. NLRC4-driven production on IL-1β discriminates between pathogenic and commensal bacteria and promotes host intestinal disease. Nat Immunol 2012, 13:449-456.
8. Shanahan F. Probiotics in perspective. Gastroenterology 2010, 139:1808-1812.
9. Deshpande G., Rao S., Patole S., et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125:921-930.
10. Tarnow-Mordi W.O., Wilkinson D., Trivedi A., et al. Probiotics reduce all-cause mortality and necrotizing enterocolitis: it is time to change practice. Pediatrics 2010, 125:1068-1070.
11. Soll R.F. Probiotics: are we ready for routine use?. Pediatrics 2010, 125:1071-1072.
12. Mihatsch W.A., Braegger C.P., Decsi T., et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr 2012, 31:6-15.
13. Blaser M.J. Heterogeneity of Helicobacter pylori. Eur J Gastroenterol Hepatol 2012, 9(Suppl 1):S3-S6. [discussion: S6-7].
14. Blaser M.J. Helicobacter pylori and esophageal disease: wake-up call?. Gastroenterology 2010, 139:1819-1822.
15. Blaser M.J., Falkow S. What are the consequences of the disappearing human microbiota?. Nat Rev Microbiol 2009, 7:887-894.
16. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical medicine: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
17. Whelan K., Myers C.E. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomised controlled trials, and nonrandomised trials. Am J Clin Nutr 2010, 91:687-703.
18. Bernardeau M., Vernoux J.P., Henri-Dubernet S., et al. Safety assessment of dairy microorganisms: the Lactobacillus genus. Int J Food Microbiol 2008, 126:278-285.
19. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46:S104-S111.
20. Abe F., Muto M., Yaeshima T., et al. Safety evaluation of probiotic bifidobacteria by analysis of mucin degradation activity and translocation ability. Anaerobe 2010, 16:131-136.
21. Sanders M.E., Akkermans L.M., Haller D., et al. Safety assessment of probiotics for human use. Gut Microbes 2010, 1:164-185.
22. Franz C.M., Huch M., Abriouel H., et al. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol 2011, 151:125-140.
23. Conen A., Zimmerer S., Frei R., et al. A pain in the neck: probiotics for ulcerative colitis. Ann Intern Med 2009, 151:895-897.
24. Ohishi A., Takahashi S., Ito Y., et al. Bifidobacterium septicaemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr 2010, 156:679-681.
25. Lapthorne S., MacSharry J., Scully P., et al. Differential M cell gene expression in response to gut commensals. Immunology 2012, 136:312-324.
26. Wagner R.D., Balish E. Potential hazards of probiotic bacteria for immunodeficient patients. Bull Inst Pasteur 1998, 96:165-170.
27. Hedin C., Whelan K., Lindsay J.O. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007, 66:307-315.
28. Steed H., Macfarlane G.T., Macfaralne S. Prebiotics, synbiotics and inflammatory bowel disease. Mol Nutr Food Res 2008, 52:898-905.
29. Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics to reduce risk and prevent or treat disease. Evidence-based practice centre under contract no. 11-E007 2011, Agency for Healthcare Research and Quality, Rockville (MD), Available at:, Accessed June 1, 2012. http://www.ahrq.gov/clinic/tp/probiotictp.htm.
30. Wallace T.C., MacKay D. The safety of probiotics: considerations following the 2011 U.S. Agency for Health Research and Quality report. J Nutr 2011, 141:1923-1924.
31. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
32. Braat H., Rottiers P., Hommes D.W., et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:754-759.
33. Vandenbroucke K., de Haard H., Beirnaert E., et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2009, 3:49-56.
34. Hamady Z.Z., Scott N., Farrar M.D., et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 2010, 59:461-469.
35. Hamady Z.Z., Scott N., Farrar M.D., et al. Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1. Inflamm Bowel Dis 2011, 17:1925-1935.
36. Besselink M.G., Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659.
37. Expression of concern - Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:875-876. The Editors of the Lancet.
38. Gooszen H.G., on behalf of the Dutch pancreatitis study group The PROPATRIA trial: best practices at the time were followed. Lancet 2010, 375:1249-1250.
39. Reid G., Gibson G., Sanders M.E., et al. Probiotic prophylaxis in predicted acute severe pancreatitis. Lancet 2008, 372:112-113.
40. Raoult D. Probiotics and obesity: a link?. Nat Rev Microbiol 2009, 7:616.
41. Ehrlich S.D. Probiotics - little evidence for a link to obesity. Nat Rev Microbiol 2009, 7:901.
42. Delzenne N., Reid G. No causal link between obesity and probiotics. Nat Rev Microbiol 2009, 7:901.
43. Million M., Angelakis E., Paul M., et al. Comparative meta-analysis of the effect of Lactobacillus species on weight gain in humans and animals. Microb Pathog 2012, 53(2):100-108.
44. Vanhee L.M., Goemé F., Nelis H.J., et al. Quality control of fifteen probiotic products containing Saccharomyces boulardii. J Appl Microbiol 2010, 109:1745-1752.
45. Masco L., Huys G., De Brandt E., et al. Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int J Food Microbiol 2005, 102:221-230.
46. Temmerman R., Scheirlinck I., Huys G., et al. Culture-independent analysis of probiotic products by denaturing gradient gel electrophoresis. Appl Environ Microbiol 2003, 69:220-226.
47. Coeuret V., Gueguen M., Vernoux J.P. Numbers and strains of lactobacilli in some probiotic products. Int J Food Microbiol 2004, 97:147-156.
48. Weese J.S. Evaluation of deficiencies in labeling of commercial probiotics. Can Vet J 2003, 44:982-983.
49. Moneret-Vautrin D.A., Morisset M., Cordebar V., et al. Probiotics may be unsafe in infants allergic to cow's milk. Allergy 2006, 61:507-508.